Csaba Gajdos MD, FACS, FSSO

Surgical Oncologist @UBSurgery | Professor @jacobs_me_ub | #SurgicalOutcomes | 🏒👨‍👩‍👦‍👦 l @asochat | @UABSurgery | @UMichSurgery

[Annals of Surgical Oncology @AnnSurgOncol]

7a. STRASS-2 is a Randomized Phase III of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High-Risk RPS @alegronchi
Link article: https://t.co/01x7uIyegk
#ASOchat

[Annals of Surgical Oncology @AnnSurgOncol]

7b. Unlike STRASS-1 where neoadjuvant RT was the variable, STRASS-2 focused on neoadjuvant chemotherapy. #ASOchat

[Csaba Gajdos MD, FACS, FSSO @Csabagajdos1]

@AnnSurgOncol Selective

[Annals of Surgical Oncology @AnnSurgOncol]

#AudioVisualAbstract : Outcomes of Distal #RectalCancer Patients Who Did Not Qualify for Watch-and-Wait: Comparison of Intersphincteric Resection Versus Abdominoperineal Resection. @Yael_Feferman @DrGarciaAguilar

https://t.co/KYx6gMQVHB

@csabagajdos1
@SyedAAhmad5

[Annals of Surgical Oncology @AnnSurgOncol]

May Issue: Predictors of Pathologic Non-response to Neoadjuvant Approaches in Locally Advanced #RectalCancer @JyiChengNg @RichardSassun

https://t.co/wf618frwb8

@csabagajdos1
@SyedAAhmad5

[NOREASTER STORM @NOREASTER1816u]

18s wrapped up Nationals prep today. 1st game tomorrow in Pittsburgh at 515 vs Anaheim. Thank you to our sponsor @FroJr18 for supporting the team this year #rollstorm

[NEJM @NEJM]

Our partnership with @DGlaucomflecken continues as he summarizes the final, 10-year outcomes of the CheckMate 067 trial, which investigated nivolumab plus ipilimumab in advanced melanoma. Access the article for free: https://t.co/phAdGwN6zj

[Csaba Gajdos MD, FACS, FSSO @Csabagajdos1]

New England district Champs U 18 AAA
Next stop is Nationals

[Csaba Gajdos MD, FACS, FSSO @Csabagajdos1]

The basics of liver surgery
@Jacobs_Med_UB, @UBSurgery, @KaleidaHealth, @UABSurgery, @UMichSurgery

[Mike Wach MD @MikeWach_MD]

@AnnSurgOncol @JamesHoweV Acknowledging it’s an uncommon manifestation, but has there been any experience with peritoneal metastases of NET? Does response to PRRT differ for those with peritoneal disease? Any role for debulking prior to PRRT? #ASOchat

[Csaba Gajdos MD, FACS, FSSO @Csabagajdos1]

@JamesHoweV @DrSabha @AnnSurgOncol How do you manage pts with intraoperative findings of small volume liver disease that did not show up on preoperative imaging ?

[Csaba Gajdos MD, FACS, FSSO @Csabagajdos1]

@OncoThor @AMVillanoMD @AnnSurgOncol @spartelli multidisciplinary approach is always the key @ASOChat @OncoThor

[Annals of Surgical Oncology @AnnSurgOncol]

“Yes, both SBNET and PNET patients had statistically significant improvements in PFS with PRRT, and OS was very close in SBNET patients (P=0.06). Smaller numbers may have contributed.” - Dr. Howe (@JamesHoweV)
#ASOchat

[Csaba Gajdos MD, FACS, FSSO @Csabagajdos1]

@OncoThor @AnnSurgOncol @JamesHoweV medical therapy with low side effect profile #ASOchat

[Csaba Gajdos MD, FACS, FSSO @Csabagajdos1]

@OncoThor @AMVillanoMD @AnnSurgOncol very interesting data

[Thor Halfdanarson @OncoThor]

@AMVillanoMD @AnnSurgOncol Retrospective data from the Netherlands also intriguing. Downstaging following PRRT is clearly possible, even at the tumor - vessel interface.

[Thor Halfdanarson @OncoThor]

@AMVillanoMD @AnnSurgOncol Paging @spartelli, my go-to expert on the subject. He led the NEOLUPANET phase 2 trial. Preoperative PRRT certainly safe and can be done but will it improve overall outcomes as well as resectability? With the ORR seen, certainly something to think about

[Csaba Gajdos MD, FACS, FSSO @Csabagajdos1]

@AnnSurgOncol Do you consider lu-Dota-tate as a fist line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors?

[Csaba Gajdos MD, FACS, FSSO @Csabagajdos1]

@AnnSurgOncol @JamesHoweV looking forward to it